Investors

Corporate Profile

Jaguar Animal Health, Inc. is an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses. Canalevia™ is Jaguar’s lead prescription drug product candidate, intended for the treatment of various forms of diarrhea in dogs. Equilevia™ (formerly referred to as SB-300) is Jaguar’s prescription drug product candidate for the treatment of gastrointestinal ulcers in horses. Canalevia™ and Equilevia™ contain ingredients isolated and purified from the Croton lechleri tree, which is sustainably harvested. Neonorm™ Calf and Neonorm™ Foal are the Company’s lead non-prescription products. Neonorm™ is a standardized botanical extract derived from the Croton lechleri tree. Canalevia™ and Neonorm™ are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar has nine active investigational new animal drug applications, or INADs, filed with the FDA and intends to develop species-specific formulations of Neonorm™ in six additional target species, formulations of Equilevia™ in horses, and Canalevia™ for cats and dogs.

Stock Quote
JAGX (Common Stock)
ExchangeNASDAQ (US Dollar)
Financial Status IndicatorD
Price$0.80
Change (%) Stock is Up 0.01 (1.27%)
Volume53,816
Data as of 04/25/17 4:00 p.m. ET
Refresh quote
Recent NewsMore News >>
Apr 06, 2017Jaguar and Napo Issue Commercial Updates
Read More
Mar 31, 2017Jaguar Animal Health and Napo Pharmaceuticals Enter Definitive Merger Agreement
Read More
Mar 28, 2017Jaguar Enters Exclusive Evaluation Period With Multinational Animal Health Pharmaceutical Firm Regarding Equilevia, Jaguar’s Drug Product Candidate for Equine Gastric Ulcer Syndrome
Read More
Mar 14, 2017Jaguar Animal Health Seeks MUMS Designation for Canalevia for Exercise-Induced Diarrhea in Dogs
Read More
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Jaguar Animal Health Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.
Print Page Print Page | E-mail Page Email Page | RSS Feeds RSS Feeds | E-mail Alerts Email Alerts | Financial Tear Sheet Financial Tear Sheet